Desmoid Tumors Respond to Sorafenib
- PMID: 30670460
- DOI: 10.1158/2159-8290.CD-NB2019-004
Desmoid Tumors Respond to Sorafenib
Abstract
A recent clinical trial shows that sorafenib is effective against desmoid tumors. The study found that 33% of tumors shrank in patients who received the drug. The estimated 1-year progression-free survival for the sorafenib-treated patients was 89%, and the 2-year rate was 81%.
©2019 American Association for Cancer Research.
Comment on
-
Sorafenib for Advanced and Refractory Desmoid Tumors.N Engl J Med. 2018 Dec 20;379(25):2417-2428. doi: 10.1056/NEJMoa1805052. N Engl J Med. 2018. PMID: 30575484 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
